生物医药科技企业Cerus Corporation最新财报显示，公司在2025年第四季度实现产品收入5780万美元，这一数字较2024年同期的业绩表现显著提升，增幅达到14%。该增长态势凸显了公司核心产品在血液安全领域的市场渗透力持续增强。
作为输血医学领域的创新领导者，Cerus Corporation专注于开发用于血液成分病原体灭活的先进技术平台。本次营收的双位数增长，印证了其INTERCEPT血液系统在全球医疗机构的采纳率稳步攀升，同时也反映出血液安全解决方案市场需求日益旺盛。
值得注意的是，这一业绩表现是在全球医疗供应链持续面临挑战的背景下取得的。公司通过优化生产流程、拓展分销网络等战略举措，成功克服外部环境压力，展现出强大的运营韧性。财务数据的稳健增长，为公司在2025财年的整体业绩奠定了坚实基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.